GlassBury AI combines agentic patient matching with culturally sensitive community education to eliminate healthcare disparities. By pairing AI with expert-curated workshops, we build the trust necessary to connect underrepresented patients with life-changing clinical trials.
AI Brain Map Predicts Early-Onset Alzheimer's Progression
When most people picture Alzheimer's disease, they imagine an individual in their late 70s or 80s gradually experiencing memory loss. However, Early-Onset Alzheimer's Disease (EOAD) paints a starkly different, often heartbreaking picture. Striking individuals under the age of 65—frequently in their 40s or 50s—EOAD attacks people who are at the very peak of their personal and professional lives.
Beyond Clearing Trash: Blocking the IDOL Enzyme Could Revolutionize Alzheimer's Care
Indiana University researchers have discovered that blocking the IDOL enzyme in neurons doesn't just clear toxic Alzheimer's plaques—it also lowers genetic risk (APOE4) and builds cognitive resilience. Read on to learn how this discovery could pave the way for a revolutionary new pill.